Yes. Pain can ease and movement can become easier without damaged tissue regrowing. Symptom relief and tissue regeneration are different outcomes, so feeling better alone cannot prove repair. In a 2026 review of 28 randomized trials involving knee osteoarthritis, intra-articular stem-cell-based therapies improved some pain and function measures compared with controls, but did not show a consistent structural benefit on MRI. That does not prove that every participant’s tissue stayed unchanged; it means reliable structural improvement was not established.[1]
This article provides general information, not personal medical advice. Discuss treatment decisions and changes in symptoms with your treating physician.

Symptom relief is not the same as tissue regeneration
Symptoms describe what you feel, such as pain or stiffness. Function describes what you can do, such as walking or climbing stairs. Tissue regeneration means restoring damaged or lost tissue; cartilage regrowth in an arthritic knee is one example. A pain questionnaire measures symptoms, not new cartilage.
A 2019 meta-analysis of 5 randomized trials involving 220 people with knee osteoarthritis found limited evidence of pain and functional benefit from injections containing mesenchymal stromal cells, often called MSCs. MRI-assessed cartilage repair did not differ significantly between groups: the standardized mean difference was 0.53, with a 95% confidence interval from −0.28 to 1.34. That interval includes no difference and reflects uncertainty, not proof that regeneration is impossible. Only two included trials were judged at low risk of bias.[2]
Why you may feel better without regrowth
Pain is not a direct measurement of tissue damage. Several changes can make an activity more comfortable without demonstrating structural repair:
- Less inflammation or irritation. A joint may hurt less when swelling settles, even if underlying cartilage loss remains.
- A change in load or support. Pacing activities, using a walking aid, or improving strength can change how a joint is loaded. Better movement does not by itself establish new tissue.
- Other care and natural fluctuation. Medication, rehabilitation and a flare settling can affect symptoms. If these occur alongside an injection, a before-and-after comparison cannot separate their contributions.
- Different measurements. A symptom score and an MRI answer different questions. Neither should be used as a substitute for the other when assessing a regeneration claim.
These are possible explanations, not a diagnosis of why an individual improved. Controlled trials help separate treatment effects from other changes; a testimonial cannot do that.
What stem cell studies actually show
The 2026 review searched the literature through December 10, 2025. Across its 28 trials, the pooled between-group mean difference in change in visual analog scale pain scores (ΔVAS) was −1.67, favoring the cell-treatment groups. The pooled difference in Knee injury and Osteoarthritis Outcome Score (KOOS) pain scores was 15.37, also favoring treatment. These are group comparisons on different scales, not percentages or the improvement every patient can expect. WOMAC and KOOS quality-of-life outcomes did not show significant between-group differences, and MRI-based whole-joint scores showed no consistent structural benefit.[1]
Cell sources, preparations, comparison treatments and study methods varied. The review’s search date is not the length of patient follow-up, and these pooled results do not establish a single duration of relief or effectiveness for a particular clinic’s product. The older review also noted the need to consider accompanying treatments. The two reviews may include some of the same trials; their trial counts should not be added together.[1][2]
Risks matter even when symptoms improve. In the 2026 analysis, injection-site pain was more frequent with cell therapies than with controls (relative risk 2.04), as was joint swelling (relative risk 3.39). These ratios are not absolute probabilities. Serious complications were uncommon in the included trials, but those findings cannot rule out rare or delayed harm.[1]
The 2019 American College of Rheumatology/Arthritis Foundation guideline strongly recommends against stem cell injections for knee or hip osteoarthritis, citing heterogeneity and a lack of standardization in preparations and techniques. A pooled symptom benefit does not remove those concerns or amount to a recommendation for a specific injection.[3]
Approval and registration answer different questions
In its April 2024 consumer information, the US FDA stated that regenerative medicine therapies were not approved for orthopedic conditions or chronic pain. That is a dated statement about these products, not a claim that no approved medicines or other treatments exist for arthritis or pain. The FDA also warned that trial listings and facility registration do not establish legal marketing, and reported blindness, tumor formation and infections associated with unapproved regenerative products.[4]
Approvals must be checked product by product and indication by indication. In December 2024, the FDA approved Ryoncil, an allogeneic bone-marrow-derived MSC therapy, for steroid-refractory acute graft-versus-host disease in children aged 2 months and older. That specific approval is not evidence of cartilage regeneration or authorization for a different joint injection.[5]
In Japan’s regenerative-medicine framework, the Ministry of Health, Labour and Welfare describes risk-based procedures and required submission of provision plans. A filed plan is not the same as marketing authorization for a product, nor does a plan number demonstrate that cartilage regrows. Research registration, provision-plan filing and approval for a defined indication should not be treated as interchangeable.[6]
How to track improvement without assuming repair
Consider a hypothetical situation: stairs feel easier after treatment, but your imaging report does not describe structural improvement. The easier climb is a useful functional observation. It does not establish new cartilage, and it does not show which part of your care caused the change.
Before your next appointment, choose a repeatable activity, such as the same short walk or flight of stairs, if your clinician considers it appropriate. Note the date, pain before and after, any walking aid, pain medicine used, and changes in rehabilitation or activity. Use the same pain scale each time. Bring the log alongside your imaging reports rather than trying to infer tissue repair from either one alone.
Ask your doctor which changes are meaningful for your diagnosis and when follow-up is needed. Relief can be worthwhile even without regeneration, but it does not automatically mean the disease has stopped progressing or that monitoring and other treatments are no longer needed.
Questions that test a regeneration claim
| Claim | What to ask |
|---|---|
| “Patients feel better.” | Which pain or function measure improved, compared with what, by how much, and for how long? |
| “The tissue regenerated.” | What structural measure supports that claim? Were scans assessed using predefined criteria and a comparison group? Did the finding persist? |
| “Studies prove this injection works.” | Do the studies match my diagnosis and disease stage, cell source and preparation, dose and injection route? What were the sample size, follow-up and adverse events? |
| “It is approved or registered.” | Which authority, product and indication? Is this product authorization, a research listing, or a provision-plan filing? |
| “It is safe because it uses cells.” | What are the absolute risks, what remains uncertain, and who handles complications and follow-up? |
If evidence is missing, treat the regeneration claim as unproven. Ask about alternatives with stronger evidence for your condition, rather than assuming that a biologically plausible mechanism guarantees a clinical result.
When discussing a treatment process in Japan, keep practical arrangements separate from the medical questions: who evaluates your diagnosis, which intervention is proposed, what it costs, and who provides follow-up after you return home.
Have questions about consultation arrangements and the information needed for an enquiry in Japan?
Contact Us for More InformationThe bottom line
Symptoms can improve without tissue regeneration. Knee osteoarthritis trials illustrate the distinction: some pain and function outcomes improved, while consistent MRI structural benefit was not established.[1][2] Value relief for what it does, but judge a regeneration claim by separate structural evidence, a relevant comparison group, sufficient follow-up and the risks of the exact intervention.




